AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Prostaglandin E synthase 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9H7Z7

UPID:

PGES2_HUMAN

Alternative names:

Membrane-associated prostaglandin E synthase-2; Microsomal prostaglandin E synthase 2; Prostaglandin-H(2) E-isomerase

Alternative UPACC:

Q9H7Z7; Q53EW9; Q5SYV6; Q96GI0; Q96GL2

Background:

Prostaglandin E synthase 2 (PTGES2), also known as Membrane-associated prostaglandin E synthase-2, plays a crucial role in the conversion of PGH2 into PGE2, a process vital for maintaining various physiological functions. Despite debates over its GSH-dependent property, PTGES2's involvement in catalyzing the degradation of PGH2 to HHT and MDA highlights its complex biological role.

Therapeutic significance:

Understanding the role of Prostaglandin E synthase 2 could open doors to potential therapeutic strategies, offering new avenues for drug discovery and development in managing diseases where prostaglandin synthesis and degradation are implicated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.